A multicenter, observational study to evaluate the safety of restarting antitumor therapy recovered from COVID-19
Restarting systemic antitumor therapy in solid tumor patients after COVID-19 recovery is generally safe. Systemic inflammatory and coagulation function of patients should be monitored during treatment.
Authors
- Chenfei Zhou (ORCID: https://orcid.org/0000-0002-9760-3216)
- Xuyang Wen (ORCID: https://orcid.org/0000-0002-9794-4379)
- Feng Qi (ORCID: https://orcid.org/0000-0003-1061-7058)
- Jun Yan (ORCID: https://orcid.org/0000-0002-5045-7338)
- Chun Wang (ORCID: https://orcid.org/0000-0002-8908-9501)
- Yang Liu (ORCID: https://orcid.org/0000-0002-7945-6611)
- Jun Zhang (ORCID: https://orcid.org/0000-0002-9709-8854)
- Qu Cai
- Qing Qu (ORCID: https://orcid.org/0000-0001-6795-2020)
- Jinling Jiang (ORCID: https://orcid.org/0000-0002-3487-0675)
- Liting Guo (ORCID: https://orcid.org/0000-0002-5987-4760)
- Qing Chang (ORCID: https://orcid.org/0000-0001-8765-2076)
- Yanzhi Bi (ORCID: https://orcid.org/0000-0002-2975-5883)
- Junwei Wu (ORCID: https://orcid.org/0009-0005-5980-9378)
- Wenqi Xi
Institutions
- Shanghai Jiao Tong University (CN)
- Ruijin Hospital (CN)
- Soochow University (CN)
- Jiading District Central Hospital (CN)
- Showa General Hospital (JP)
- 82th Hospital of Pla (CN)
- Shanghai University of Medicine and Health Sciences (CN)
- Tongji Hospital (CN)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-12-03
- DOI
- https://doi.org/10.1080/14796694.2025.2595908
- Primary Topic
- COVID-19 and healthcare impacts
- Type
- article
- Field-Weighted Citation Impact
- 0.00